Wiley Bros. Aintree Capital, LLC Argenx Se Transaction History
Wiley Bros. Aintree Capital, LLC
- $5.07 Billion
- Q3 2024
A detailed history of Wiley Bros. Aintree Capital, LLC transactions in Argenx Se stock. As of the latest transaction made, Wiley Bros. Aintree Capital, LLC holds 753 shares of ARGX stock, worth $494,163. This represents 0.01% of its overall portfolio holdings.
Number of Shares
753
Previous 480
56.88%
Holding current value
$494,163
Previous $206,000
98.06%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding ARGX
# of Institutions
403Shares Held
30.8MCall Options Held
376KPut Options Held
489K-
Price T Rowe Associates Inc Baltimore, MD5.82MShares$3.82 Billion0.36% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.51MShares$2.31 Billion2.99% of portfolio
-
Janus Henderson Group PLC London, X02.48MShares$1.63 Billion0.72% of portfolio
-
Capital World Investors Los Angeles, CA1.7MShares$1.12 Billion0.15% of portfolio
-
Avoro Capital Advisors LLC New York, NY1.24MShares$813 Million10.11% of portfolio
About ARGENX SE
- Ticker ARGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,323,800
- Market Cap $36.3B
- Description
- argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...